You are herePharma News

Pharma News


Health Ministry : Now Clinical Trials will be evaluated on parameters given by Supreme Court

(12th September, 2014); Now in India, all the Global Clinical Trials (GCTs)/New Clinical Trials (NCEs) should be evaluated on regard to parameters given by Honorable supreme court. Drugs controller general of India (DCGI) clearly mentioned on all parameters in their notice.


Simple method develops white blood cells from human skin

(12th September, 2014); For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.


4th International Congress on Patient Safety and 5th International Conference on Transforming Healthcare with IT 2014 hosted for the First Time in Eastern India by Apollo Gleneagles Hospitals

(9th September, 2014; Business Wire India); In its endeavour to build awareness and consciousness Apollo  Hospitals in association with ISQua, JCI, NABH and many other institutions hosted the 4th International Congress on Patient Safety along with the 5th edition of International Conference on Transforming Healthcare with IT 2014 for the first time in the Eastern part of the country. The two day event took place on 5th and 6th of September, 2014 at ITC Sonar, Kolkata.


Increased possibilities in India-Australia health care cooperation

(7th September, 2014); India and Australia are exploring cooperation possibilities in preventive healthcare, trauma care, geriatric medicine, diabetes research and mental illnesses. This found iteration in the dialogue held between the visiting Prime Minister of Australia, Mr Tony Abbott, and the Union Health Minister, Dr Harsh Vardhan, on 5th Sept, Friday.


Japan – India Cooperation in Healthcare: Rockland Takes the Initiative

(5th September, 2014; Business Wire India); “India & Japan have a big opportunity of working together in the area of healthcare. Japan has achieved its goal of longevity and healthy life for all its citizens. This knowledge and technology will benefit India as well as the rest of the world. Shri Narendra Modi, Hon’ble Prime Minister of India, has already extended an open invitation to COME MAKE IN INDIA.  India will give Japan a huge consuming population, excellent human resources and a low cost base for manufacturing and exporting healthcare solutions to the world”, said Rajesh Srivastava, Chairman, Rockland Hospitals. He was speaking on the topic: Creating Healthcare Access for Cancer Treatment: Sharing Japanese Solutions, during a two days seminar titled FICCI- Heal-2014 on 1 & 2 Sept in Delhi.


Florida scientists made Diseased Cells to synthesize their own drug to treat muscular dystrophy

(4th September, 2014); Florida Scientists from The Scripps Research Institute (TSRI) have considered chemical approach to convert diseased cells to be manufacturing site of a molecule which can treat muscular dystrophy. The promising research was published recently in the international chemistry journal Angewandte Chemie.


Mississippi Baby taught important HIV Lessons

(3rd September, 2014); The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized by the possibility of a cure. But a new commentary by two leading HIV experts at Johns Hopkins argues that despite its disappointing outcome, the Mississippi case and two other recent HIV "rebounds" in adults, have yielded critical lessons about the virus' most perplexing - and maddening - feature: its ability to form cure-defying viral hideouts.



Angiotensin receptor-neprilysin inhibitor opens new horizon in cardiac failure

(3rd September, 2014); The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. And surprisingly, LCZ696 was superior to ACE-inhibitor, enalapril, on key endpoints in the largest heart failure study ever done.


GSK and NIAID initiates First Human Trial for Ebola Vaccine

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin soon by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.


Two drugs from Wockhardt received Qualified Infectious Disease Product (QIDP) status from the USFDA

(2nd September, 2014); Wockhardt Ltd’s New Drug Discovery program in Anti - Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.